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Intrinsic coating morphology 
modulates acute drug transfer in 
drug-coated balloon therapy
Gary H. Chang1, Dara A. Azar2, Chimera Lyle3, Vipul C. Chitalia  3,4,6, tarek shazly2 & 
Vijaya B. Kolachalama  1,4,5
the hallmark of drug-coated balloon (DCB) therapy for the treatment of peripheral vascular disease 
is that it allows for reopening of the narrowed lumen and local drug delivery without the need for a 
permanent indwelling metal implant such as a stent. Current DCB designs rely on transferring drugs 
such as paclitaxel to the arterial vessel using a variety of biocompatible excipients coated on the 
balloons. Inherent procedural challenges, along with limited understanding of the interactions between 
the coating and the artery, interactions between the coating and the balloon as well as site-specific 
differences, have led to DCB designs with poor drug delivery efficiency. Our study is focused on two 
clinically significant DCB excipients, urea and shellac, and uses uniaxial mechanical testing, scanning 
electron microscopy (seM), and biophysical modeling based on classic Hertz theory to elucidate 
how coating microstructure governs the transmission of forces at the coating-artery interface. seM 
revealed shellac-based coatings to contain spherical-shaped microstructural elements whereas 
urea-based coatings contained conical-shaped microstructural elements. our model based on Hertz 
theory showed that the interactions between these intrinsic coating elements with the arterial wall 
were fundamentally different, even when the same external force was applied by the balloon on the 
arterial wall. Using two orthogonal cell-based assays, our study also found differential viability when 
endothelial cells were exposed to titrated concentrations of urea and shellac, further highlighting the 
need to maximize coating transfer efficiency in the context of DCB therapies. Our results underscore the 
significance of the excipient in DCB design and suggest that coating microstructure modulates acute 
drug transfer during device deployment.
Peripheral arterial disease (PAD) was estimated to affect over 200 million people around the world in the preced-
ing decade and this number is increasing continuously1,2. Endovascular interventions such as percutaneous 
transluminal angioplasty (PTA) with or without stenting are among the preferred choices for the treatment of 
PAD. Recent randomized controlled clinical trials have demonstrated the superiority of drug-coated balloon 
(DCB) therapy when compared to PTA alone, at least in terms of improved patency and reduced target lesion 
revascularization3–7. In all these studies, paclitaxel (PTX) was the drug of choice but each device differed in terms 
of the drug dosing, the selection of the excipient and the overall coating formulation. For example, two DCBs 
that have recently obtained regulatory approval within the United States have 3.5 µg/mm2 of PTX with urea as the 
excipient (IN.PACT Admiral, Medtronic, Santa Rosa, CA, USA), and 2 µg/mm2 of PTX with a mixture of poly-
sorbate and sorbitol as the excipient (Lutonix DCB, C. R. Bard, New Hope, MN, USA), respectively. Additionally, 
few DCBs that are undergoing clinical trials as well as the ones in development also use PTX as the drug, (e.g. 
Stellarex DCB, Spectranetics, Colorado Springs, CO, USA containing 2 µg/mm2 of PTX with polyethylene gly-
col as the excipient). During the endovascular procedure, the belief is that an optimal coating enables efficient 
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transfer of drug from the balloon to the artery, with concomitant adherence to the arterial wall. The adhered 
coating is then expected to serve as a sustained drug source, leading to a second phase of drug delivery to the 
arterial wall. Studies have shown that only a small portion (<8%) of the coating gets transferred during balloon 
inflation8, and almost 90% of the delivered drug is lost within about 24–48 hours9. These numbers point to the 
poor efficiency of drug delivery from balloon catheters. Hence, there is a need to better understand the factors 
influencing delivery efficiency and what causes these persistent limitations10,11.
We sought to examine the interactions between the balloon coating and the arterial wall on multiple 
scales to better understand device-dependent arterial pharmacokinetics. We selected PTX as the drug along 
with urea and shellac as the excipients for the balloon coating in our experimental study. While a balloon 
catheter using urea as an excipient is already in clinical use within the United States (IN.PACT Admiral, 
Medtronic) for the treatment of PAD6,7, a DCB device with shellac as the excipient (DIOR II, Eurocor) is 
approved in the European Union for coronary applications12. First, we performed a series of bench-top 
experiments to estimate coating-specific mechanical behavior that allowed us to characterize the contact 
between the balloon coating and the arterial wall. Using these parameters, we developed a biophysical model 
to quantify the interfacial mechanics as a function of the intrinsic shape of the coating microstructure and 
the force applied by the balloon on the arterial wall. Developed metrics of interfacial mechanics were then 
associated with experimental measurements of arterial drug transfer. To further quantify excipient-based 
differences among potential DCBs, we examined cultured human endothelial cell viability when treated with 
increasing concentrations of urea and shellac. While the mechanical tests and modeling relate to essential 
device function at the time of DCB deployment, the latter studies are relevant to the notion of increasing 
coating adherence/retention to serve as a sustained drug source. Taken together, obtained results underscore 
the importance of coating composition as a determinant factor of DCB efficiency and suggest that coating 
microstructure modulates the acute drug delivery from these devices.
Materials and Methods
Preparation of PTX-excipient coated and control films. We developed balloon coatings with PTX 
and urea (1:1), as well as with PTX and shellac (1:1), using a micropipetting-coating method. Briefly, urea and 
shellac, 5–20% w/v, were dissolved in ethanol-200 at ~200 rpm for 4–6 hours. PTX solution was prepared in eth-
anol-200 at 10 mg/mL and added dropwise to the excipient solutions to generate several (5–20%) w/v mixtures. 
Each solution was then micropipetted on a sheet of balloon material (Nylon-12), and was kept at room tempera-
ture for 6 hours, which resulted in a coated surface with 3 µg/mm2 PTX with either excipient. The dried films were 
cut in 25 × 25 mm squares and glued to a rigid 3D-printed testing block, creating flat test elements for uniaxial 
mechanical testing (Fig. 1A).
Mechanical characterization of coated balloon in isolation. The compressive mechanical response 
of coated balloons was measured using a mechanical testing system (Bose ElectroForce 5270) configured for 
uniaxial testing. The created test elements were placed between two flat plates, and subjected to a compressive 
displacement (0.005 mm/sec) until the force response was 1, 2 or 3N. Once the target force was reached, the 
compression plates were held at the same position for a dwell time of 60 s, following by unloading of the sample 
at the same displacement rate. Sample force and displacement data (Fig. 1B), were continuously recorded at an 
acquisition rate of 20 s−1 using a system-integrated software (Wintest).
To facilitate calculation of the reduced modulus of the coated balloon, the resultant force-displacement data 
were fit to a two-term exponential model, defined as:
Figure 1. (A) Mechanical testing setup customized for uniaxial compression testing. Schematic of the 
2-element test system containing the arterial vessel and the drug-coated balloon is also shown. (B) A typical 
force-displacement (FD) curve that results from a mechanical test. Data resulting from the FD curve was used 
to estimate compliance values of the test construct.









where F is the recorded compressive force, δb is the displacement, and αi are the parameters for the exponential 































Mechanical characterization of coated balloon in contact with arterial vessel. During balloon 
inflation, the coating contacts and directly interacts with the arterial wall. To facilitate procedural simulation with 
our coated balloon test elements, we created analogous flat arterial tissue elements from porcine femoral arteries 
obtained from a local abattoir immediately following animal sacrifice (8–12-month-old, 75–125 lbs, male 
American Yorkshire pigs). We configured these two elements – the coated balloon and arterial tissue sample – in 
series to enable uniaxial compression testing (Fig. 1A). The same loading-dwell-unloading protocol as described 
above was applied to this 2-element system. Obtained data allowed relation of the overall compliance of this 





































































































Figure 2. Force-displacement curves. (A–C) Average force-displacement curves generated from the 
compression test. Curve-fitting results for the shellac coated balloon with application force of 1N (A), 2N (B) 
and 3N (C) are shown. (D–F) Average force-displacement curves for the compression test, followed by curve-
fitting results for the urea coated balloon with application force of 1N (D), 2N (E) and 3N (F) are shown.
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where δ0 is the total displacement of the 2-element system, F is the recorded compressive force, A is the overall 
contact area between the balloon coating and the arterial wall, ⁎Eb  and 
⁎Et  are the reduced moduli of the balloon 
and arterial wall, respectively13,14.
scanning electron microscopy. Variable pressure scanning electron microscopy (SEM) (Tescan Vega-3 
SBU) was used to assess the surface microstructure of the coated balloons. Obtained images were processed to 
measure the average intrinsic shape of the coatings (Matlab, MathWorks, Natick, MA). Each SEM image was 
first converted to grayscale and then binarized. The ‘regionprops’ feature was used to read all the objects within 
the binarized image and several properties including mean perimeter and mean contact angle were estimated 
that defined the intrinsic shape of shellac and urea microstructures, respectively (Fig. 3A,B). For shellac, we 
observed a spherical microstructure, whereas for urea, we noticed a micro needle-like structure with a polygonal 
cross-section along the length of the needle, thus representing a conical contact with the arterial surface. Note 
that the conical contact assumption was made for cases when the micro needle was lying flat on the arterial sur-
face or when the tip of the micro needle was in contact with the arterial surface.
Contact mechanics model. We modeled the interactions between the balloon coating and the artery 
during balloon angioplasty as an elastic contact problem using the classic Hertz theory. The surface of the bal-
loon coating has a unique microstructure characterized by its intrinsic shape and asperity. For PTX-shellac, we 
assumed that when the spherical microstructures come in contact with the arterial vessel, they result in an elastic 
deformation within the region of the point of contact. This contact region is smaller than the surface area of the 
spherical element and is defined using (Fig. 3C):
δ=a R , (5)0
where a0 is the contact radius, δ is the indentation depth, and R is the radius of the intrinsic spherical element15,16. 
The resulting force applied by the spherical element on the arterial wall then becomes:




where ⁎Et  is the reduced elastic modulus of the arterial wall. While the force applied results in the elastic interac-
tion between the spherical coating element and the arterial wall, only the contact region experiences this force. 
Thus, the distribution of this force over a smaller region is quantified by the mean contact pressure π=P F a/( )0 0
2 . 
For PTX-shellac, this becomes:
Figure 3. Intrinsic shape of the balloon coatings. SEM imaging revealed a spherical structure for shellac 
(A), and conical structure for urea (B). Contact mechanics models were developed based on Hertz theory by 
considering a spherical element for shellac (C) and a conical element for urea (D).








For the case of PTX-urea, the observed needle-like structures were considered as conical structures with sharp 






where θ is the angle (assumed as 30°) between the conical shape and the indented surface15,17. The total force 















Measurement of arterial drug transfer. Stored arterial vessel samples (obtained after mechanical testing) 
were prepared for high-performance liquid chromatography (HPLC) to measure the amount of transferred drug. 
Each sample was first submerged in methanol and vortexed briefly. The vessel was then homogenized in metha-
nol for 3 minutes using a probe sonicator and vortexed again for 10 minutes. The sample was then centrifuged at 
1000 rpm for 10 minutes. The supernatant holding the extracted drug was transferred to a fresh experiment tube. 
This sample was diluted in methanol and readied for HPLC testing. The extraction method above was validated 
by two control experiments; dissolving known amounts of drug in methanol and loading drug (paclitaxel) onto 
vessel samples followed by rapid freezing, extraction using methanol and dilution prior to HPLC. Then, standard 
solutions and sample solutions were analyzed through HPLC.
Cell culture. We performed cell culture experiments to determine if the presence of different balloon coating 
materials would affect cell viability. Human umbilical endothelial cells were cultured as described previously18. 
Cells were maintained at 37 °C and 5% CO2. Early passage cells (less than eight passages) were used for the study.
Flow cytometry. To examine the cytotoxicity of the excipients on live cells, LIVE/DEAD staining followed 
by analysis was conducted. Endothelial cells (2 × 105) were plated in 12 well plates and were treated for 24 hours 
with a titrated concentration of the shellac and urea. Molecular grade ethanol (Pharmco) was used to dissolve 
shellac (Sigma Aldrich) (10 µM–100 mM) and double distilled autoclaved water was used to dissolve urea (Sigma 
Aldrich) (10 µM–100 mM). Single cell suspensions were analyzed using FACS LSR II (BD Biosciences). Cells 
were harvested and viable versus non-viable cells determined by staining with Zombie UV™ Fixable Viability Kit 
(Biolegend), as described previously19,20. Cells were stained in dark conditions for 30 minutes at room tempera-
ture in protein free phosphate buffered saline. Gating was done on live cells whose intact membranes prevent dye 
infiltration while dye positive dead cells were excluded. The positive control consisted of dead cells, which were 
induced using Staurosporine21. Data were analyzed with Flowjo software (Tree Star).
Cell viability assay. To examine the cytotoxicity of the excipients, viability of the cells was determined by 
measuring released ATP using the Cell Titer–Glo Luminescent assay (Promega) performed using manufactur-
er’s instructions. Endothelial cells (5 × 104/100 µL) were plated on a 96 well plate and treated with various con-
centrations of 200 proof ethanol (Pharmco) dissolved shellac (10 µM–100 mM) and double distilled autoclaved 
water dissolved urea (10 µM–100 mM) for 24 hours. Cell Titer Glo buffer and substrate were equilibrated to room 
temperature. The buffer was added to the lyophilized substrate and mixed gently using vortexing. Equal volume 
(100 µL) of the homogenous solution was added to the plated cells. Luminescence was measured with a plate 
reader. Luminescent signal is proportional to the amount of ATP. Presence of ATP is directly proportional to the 
number of viable cells in culture. Data were analyzed with GraphPad Prism.
statistical analysis. Descriptive statistics are presented as the mean and standard deviation. Unpaired 
Student’s t-test was used to compare experimental groups as appropriate. For some cases, significance of the 
Pearson correlation coefficient was computed using two-tailed probability, given the correlation value (R2) and 
the sample size. A p-value less than 0.05 was considered statistically significant.
Results
surface morphology of the coatings. SEM imaging allowed us to characterize the distinct morphologic 
structures of PTX-urea and PTX-shellac, respectively (Fig. 3A,B). We performed image processing on the SEM 
images to measure the intrinsic shape and the number of microstructures per unit area of the coating micro-
structures. The shellac coating consisted of spherical microstructures with a mean radius of 0.84 µm and a stand-
ard deviation of 0.30 µm (Fig. 3A), and the microstructures distributed densely with 0.18 microstructures per 
square micrometer. The urea coating consisted of needle-like cyrstalline mircostructures with a mean length of 
21.6 µm and a standard deviation of 8.5 µm (Fig. 3B), and the microstructures distributed more sparsely with 
0.003 microstructures per square micrometer. As these surface morphologic signatures can lead to dissimilar 
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modes of interaction with the arterial vessel, we hypothesized that these modes can also lead to differential drug 
transfer patterns. Additionally, the Hertz theory allowed us to relate SEM-observed intrinsic shapes of the coat-
ings to define the contact regions between the balloon coating and the vessel wall.
Mechanical properties of the test elements. We leveraged uniaxial compression testing to simulate the 
coating-artery interaction during angioplasty. The compression phase of the experiment simulates balloon inflation, 
which was reflected as a gradual increase in tissue displacement with increasing applied compressive force. The com-
pressive moduli of the test samples were calculated from the force-displacement (FD) curves during the compression 
phase. During the 60 s displacement dwell period, the test constructs underwent a relaxation phase, as indicated by the 
gradual reduction in compressive force. During the decompression phase, the coating is separated from the contact 
region and the applied force gradually returns to zero, indicating complete interfacial failure, which could be attributed 
to adhesive failure of formed interface and/or fracture of the balloon coating (Fig. 1B).
The first set of mechanical testing experiments generated FD curves during the compression phase when 
shellac- and urea-coated balloons were compressed on flat, rigid surfaces, respectively (Fig. 4A,B). These exper-
iments allowed us to estimate the mean compliance values of both the urea- and shellac-coated balloons at the 
maximum compressive force of 1, 2 and 3N, respectively (Fig. 4C). Interestingly, there were no statistically sig-
nificant differences between the mean compliance values of shellac- and urea-coated balloons (p = 0.36 for 1N, 
p = 0.41 for 2N and p = 0.62 for 3N). The second set of mechanical testing generated FD curves during the com-
pression phase when shellac- and urea-coated balloons were compressed on excised femoral arteries opened en 
face so that the intraluminal side of the vessel was in contact with the balloon coating (Fig. 4D,E). Mean overall 
compliance values of the 2-element test constructs were then computed (Fig. 4F). Even for this set of experiments, 
we found no statistically significant differences between the mean overall compliance values of shellac and urea 
(p = 0.27 for 1N, p = 0.87 for 2N and p = 0.84 for 3N). Later, for each experiment that generated a unique FD 
curve during the compression phase, the compliance of the arterial vessel used for that experiment was then 
computed as the net difference between the overall compliance of the 2-element system and the estimated average 
compliance of the coated balloon. In this fashion, we were able to compute arterial sample-specific estimates of 
compliance, and these values were used further to quantify the coating-artery interactions. Taken together, these 
results imply that within our experimental design space and under the examined mode of coating-tissue interac-
tion, bulk interfacial mechanics are insensitive to excipient type.
Relating coating-specific interactions with arterial drug transfer. We hypothesized that coating 
surface microstructure impacts the interactions between the coating and the arterial wall. We computed the mean 
contact pressure for each coating, which is a function of the applied force and the contacting surface area of the 
Figure 4. Bulk interfacial mechanics are independent of excipient type. Force-displacement (FD) curves from 
the mechanical test when shellac (A) and urea (B) were used as the balloon coating materials, respectively. For 
(A,B), the test element comprised of the balloon coating compressed on a flat, rigid surface, which allowed us 
to estimate the balloon compliance (C) of shellac (indicated by the abbreviation SH) and urea (indicated by the 
abbreviation UR), respectively. FD curves from the mechanical test when shellac (D) and urea (E) were used as 
the balloon coating materials, respectively, where the test element comprised of the balloon coating compressed 
on an excised porcine arterial vessel. This experiment allowed us to estimate the overall compliance values of the 
2-element system (F) with shellac and urea, respectively. The dwell time was maintained at 60 s with a maximum 
application force of 3N.
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coating (Fig. 5A). Interestingly, we found statistically significant differences in the mean contact pressure values 
between shellac and urea as a function of application force (p = 1.2e-2 for 1N, p = 3.3e-3 for 2N and p = 7.6e-4 
for 3N). We also found that the size of the contact region was different between urea and shellac, respectively 
(Fig. 5B), regardless of the amount of application force (p = 1.0e-4 for 1N, p = 6.0e-4 for 2N and p = 2.2e-3 for 
3N). Importantly, acute drug transfer following mechanical testing correlated with mean contact pressure in a 
coating-specific fashion (Fig. 5C; R2 = 0.45, p = 1.3e-2 for urea and R2 = 0.05, p = 0.465 for shellac). These results 
indicate a stronger correlation of drug uptake with mean contact pressure in the case of urea than for shellac. 
Systematic analysis in this fashion can allow us to quantify these relationships to a broad range of candidate 
excipients.
Cytotoxicity of the excipient. While the coating shape-dependent aspects associated with corresponding 
transfer of the balloon coating, the task was to determine how these coatings behaved within the cellular envi-
ronment. As such, DCBs are placed within the vessel wall, which exposes the coating directly to the vascular 
endothelium. To this end, human umbilical endothelial cells were exposed to titrated concentrations of shellac 
and urea for 24 hours. The cells were subjected to LIVE/DEAD and ATP release assays, respectively. Both these 
assays showed that low concentrations (10 µM/mL) of shellac and urea did not affect cell viability compared to 
vehicle treated cells (Fig. 6A,B). However, shellac from 10 µM to 100 µM resulted in an increase from 8.5% cell 
death to 30.5% cell death. This change was not found in similar concentrations of urea. Increasing the concen-
tration of urea from 10 µM to 100 µM, did not affect cell viability and this trend continued up to a 10,000-fold 
increase of urea to 1 mM. These data corroborated with the luminescent cell viability assay (Fig. 6C). Shellac 
demonstrated a dose-dependent decrease in cell viability. Cells treated with higher dosages of shellac resulted in 
decreased ATP levels when compared to cells treated with the same concentration of urea (Fig. 6D). Since the 
presence of ATP is an indicator of metabolically active cells, this assay strongly suggests that shellac potentially 
decreases cell viability at high concentrations. Collectively, both these assays consistently showed lower viability 
at an eqimolar concentration of shellac compared to urea.
Discussion
Catheter-based endovascular therapy involving balloon angioplasty in concert with local drug delivery is highly 
appealing as it circumvents the use of permanent indwelling implants such as stents9,22–27. Balloon angioplasty 
alone or angioplasty followed by stenting as such have stood the test of time28, and their strengths as well as lim-
itations are appreciated by the clinical community. On the other hand, clinical studies focused on intraluminal 
delivery of therapeutic compounds from these balloon catheters have demonstrated great promise but have not 
yet fully proven to result in a sustained, long-term benefit6,29,30. Balloon-vessel contact times are short due to the 
nature of the procedure (2–3 min), and moreover, the process of coating transfer from the balloon to the vessel 
wall and drug delivery efficiency within this period are not fully understood. Continuation of this trend can lead 
















































Figure 5. Excipient microstructure modulates acute transfer of balloon coating. Mean contact pressure was 
computed by normalizing the application force with the intrinsic shape of shellac (A) and urea (B). Normalized 
contact radius was different between shellac (C) and urea (D) as well. Asterisks indicate statistical significance 
(p < 0.05). (E) Net coating transfer as a function of mean contact pressure for urea and shellac. Data on both 
axes is plotted in log-10 scale.
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to a problem - DCB therapy could remain under-appreciated and interventional strategies for PAD using cur-
rently approved DCBs can lead to sub-optimal outcomes. It is therefore important to identify factors that promote 
efficient delivery and track consequent arterial pharmacokinetics.
Using a series of bench-top experiments and modeling the interaction between the balloon coating and the 
arterial wall (Fig. 1), we computed compliance values of the arterial wall and mean compliance values of the bal-
loon coating. Using the classic Hertz theory, we defined shape-specific contact mechanics and the contact force 
applied on the arterial wall. Mean contact pressure, which is a function of the contact force and the intrinsic shape 
of the coating, was then computed for each of these cases and associated with corresponding acute transfer of 
the balloon coating (Fig. 5E). Also, endothelial cells exposure to either shellac or urea, induced differential toxic 
effects that were dose-dependent (Fig. 6). These results underscore the importance of fully characterizing the 
nature of the excipients so as to optimize DCB therapy.
The DCB excipient has an important role to play before, during and after balloon angioplasty. During the 
pre-procedural or the design phase, a coating technique is used to create a thin layer on the surface of the balloon, 
where the excipient directly plays a role to support adhesion of the coating to the balloon. During the procedure, 
as the balloon is expanded to reopen an occluded arterial vessel, a portion of the balloon-adhered drug coat-
ing detaches from the balloon and gets transferred to the arterial wall. Here, the excipient acts as the carrier to 
facilitate rapid drug transfer to the mural surface. The procedural time is short (~2–3 minutes) but can be logi-
cally considered as 2 sub-phases defined as the compression and decompression of the tissue-balloon interface 
(Fig. 1B). During the compression sub-phase, the coating is adhered to the balloon and concomitantly initiates 
Figure 6. Cytotoxicity of the excipients. (A,B) Cell death with increasing concentrations of shellac and urea. 
Endothelial cells (1 × 106) were treated for 24 hours with increasing concentrations of shellac and urea. Cells 
were harvested and stained with Zombie UV™ viability fluorescent dye and analyzed by flow cytometry. Heat-
shocked cells were used as positive control. Ethanol was used as a vehicle control for shellac and water for urea. 
Representative FACS images from two independent experiments is shown. Increase in concentration of urea did 
not result in decreased cell viability. (C) Average percentage of live cells in response to the treatment of shellac 
and urea done in two independent experiments is shown. The symbol * indicates p-value that compares live 
cells between shellac and urea-treated samples. Also, p = 0.03 for 100 µM, p = 0.005 for 200 µM, p = 0.017 for 
500 µM, p = 0.004 for 1000 µM. Standard errors are shown on error bars. (D) Average of ATP production from 
two independent experiments is shown. ATP production indicates the viability of endothelial cells as a function 
of increasing concentrations of urea and shellac. The symbol * indicates p-value that compares ATP between 
shellac and urea-treated cells. Also, p = 0.02 for 100 µM, p = 0.001 for 200 µM, p = 0.001 for 500 µM, p = 0.01 for 
1000 µM. Increase in concentration of urea did not compromise ATP production in endothelial cells. Standard 
errors are shown on error bars.
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contact with the mural surface. This mechanical contact initiated due to the radially outward force generated by 
balloon expansion leads to adhesion of the coating to the mural surface. Several properties of the excipient play 
a role in terms of dictating the extent of adhesion. During the decompression sub-phase, the radially inward 
force generated by balloon deflation generates interfacial failure between the mural surface and the drug coating 
and potentially between the balloon and the drug coating. Cohesive bond failure within the coating itself is also 
a possibility during the decompression sub-phase. Once the procedure is completed, the expectation is that the 
transferred drug coating continues to adhere to the mural surface, which can lead to a sustained therapeutic 
response. In this phase, the excipient acts as an agent to support adhesion and creates a source for local delivery of 
drug to the mural surface. In sum, the pre-procedural design considerations, the procedural aspects involving dif-
ferent modes of bonding failure and post-procedural phenomenon related to mural adhesion of drug coating can 
together determine the success of DCB delivery. As a first step towards fully characterizing the role of excipients, 
we focused on quantifying the impact of coating surface morphology and its interaction with the mural surface 
during the procedure on acute transfer of the balloon coating.
Our study’s main finding is that the unique microstructure of the balloon coating can directly impact acute 
transfer of the balloon coating. This is due to the fact that at this scale, the interaction between a spherical-shaped 
element and the arterial wall is fundamentally different from that of a conical-shaped element, even when the 
same external force is applied by the balloon on the arterial wall. The classic Hertz theory allowed us to math-
ematically decompose this deterministic aspect of contact mechanics (Fig. 3C,D) in terms of the mean contact 
pressure associated with a specific excipient and application force (Fig. 5A,B). We found distinct differences in 
balloon transfer of paclitaxel as a function of mean contact pressure for urea and shellac (Fig. 5E).
Our study has some limitations. We used explanted porcine femoral arteries for mechanical testing and for 
subsequent measurements of drug transfer. These vessels may lose some structural integrity immediately after 
sacrifice, even though we took utmost care to preserve tissue viability. Our uniaxial mechanical testing protocol is 
designed to isolate contact phenomena that likely underlie DCB performance, but does not mimic exact clinical 
deployment of these devices. We assumed linear elastic behavior for all components in our contact mechanical 
model, although nonlinear effects may become important at larger strains/strain rates experienced in device 
deployment. During mechanical testing, both cohesive and adhesive bond forces play a role during compression 
and decompression phases, respectively, and this dynamic may ultimately determine the amount of drug coating 
adhered to the vessel wall. We did not attempt to isolate the individual roles of cohesion and adhesion in the con-
text of our study, as our goal was to estimate metrics relevant to balloon-tissue contact and acute drug transfer. 
This type of bonding failure (adhesive or cohesive) will dictate the amount of drug coating that is retained on 
the mural surface under physiologic conditions (i.e. blood flow), and is thus significant to drug retention at the 
application site.
In conclusion, our study connects the application force, which is a procedural factor that exemplifies balloon 
angioplasty with the intrinsic shape of the balloon coating microstructure, which is a design parameter of the 
device itself. By relating the coating-specific morphology and its subsequent interactions with the arterial vessel, 
we have demonstrated a mechanistic basis by which to evaluate different balloon coatings. While examination of 
bulk interfacial mechanics found no coating-specific differences, mean contact pressure computed by normal-
izing the application force with the intrinsic shape of the coating was significantly different between urea and 
shellac. This means that no two excipients can be alike in terms of their microscopic mechanical interactions with 
the arterial vessel, and when coated on the balloons along with the same drug can still result in differential arte-
rial pharmacokinetics. Our paradigm can be further used to design coating formulations that can have maximal 
balloon transfer of drug, higher arterial uptake and minimal loss within the systemic circulation, thereby paving 
way towards efficient therapeutic approaches using balloon catheters.
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